CClinicalTrials.gg
Status unknownNCT01879982PSYCHEUpdated Jun 18, 2013

PSYCHE (Personalised Monitoring SYstems for Care in Mental Health)

An observational study in Bipolar Disorder I, Bipolar Disorder II and Rapid Cycling Bipolar Disorder(DSM-IV-TR), sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-06-18.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified Jun 2013), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
8
Ages
18 Years to 65 Years
Sex
All
01

Study summary

For the moment, the detection of a mood episode in Bipolar Disorder (BD) relies on the appearance of the first clinical signs that the clinician detect or that the patient becomes aware of and reports to the clinician. Since physiological parameters such as cardiac rhythms, respiratory rate, voice characteristics and actigraphy seem to be related to the onset of a mood episode, information collected through the combined monitoring of multiple selected physiological parameters (such as cardiac rhythms, respiratory rate, movements, voice) during wake and sleep time, using wearable user friendly systems included into garments as well as with a smartphone, may offer a new perspective in the long-term treatment of BD.

02

Conditions studied

  • Bipolar Disorder I
  • Bipolar Disorder II
  • Rapid Cycling Bipolar Disorder(DSM-IV-TR)

Browse trials for

Keywords

  • Bipolar disorder
  • subtypes
03

In context

Bipolar Disorder

1,601 studies on the registry are indexed under Bipolar Disorder; 254 are open to participants now.

This study's planned enrollment of 8 is below the median of 160 across 329 observational studies indexed under Bipolar Disorder.

Browse Bipolar Disorder studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with cyclothymia or with rapid cycling BD will be recruited in the general population via ads in newspapers and universities (psychology, medical, and arts departments, for instance) and in clinical populations (patients from the investigators).

Inclusion criteria

  1. Male and female individuals aged from 18 to 65 years old (both ages included).
  2. Participants meeting DSM-IV-TR criteria for bipolar disorder I or II subtypes or Participants meeting DSM-IV-TR criteria for rapid cycling BD, which is defined by a pattern of presentation accompanied by 4 or more mood episodes in a 12-month period, with a typical course of mania or hypomania followed by depression or vice versa. The episodes must be demarcated by a full or partial remission lasting at least 2 months or by a switch to a mood state of opposite polarity.
  3. Female participants must agree to use efficient contraceptive methods during the study duration.
  4. Participants must have signed informed consent documents indicating that they understand the purpose and procedures required for the study and are willing to participate in the study and comply with the study procedures and restrictions.
  5. Patients must be affiliated with or a beneficiary of a social security system.

Exclusion criteria

Exclusion Criteria:

  1. Any clinically relevant acute or chronic diseases which could interfere with the participants' safety during the trial, or expose them to undue risk or which could interfere with the study objective. This last perspective includes :- Attention deficit and hyperactivity disorder (ADHD)- Borderline personality disorder (BPD)
  2. Current MDD episode or manic episode, according to the DSM-IV-TR criteria
  3. Current major suicidal ideation (suicidal thoughts several times a day)
  4. History of recent (less than 1 year preceding inclusion) substance abuse or dependence (tobacco dependence excepted)
  5. Pregnant women as determined by the patient or breast-feeding women
  6. Any history of significant allergy.
  7. No legal capacity or limited legal capacity or unable to give an informed consent.
  8. Participants unlikely to co-operate in the study, and/or poor compliance anticipated by the investigator
  9. Participants being in the exclusion period according to the French National File for participants participating in a biomedical research.
  10. Total annual amount of compensation earned from participating in clinical studies exceeding 4500 Euros.
  11. Patients with pacemaker, defibrillator, or any implanted electronic device (to avoid any hazard - see section 7.3.2 of the Psyche device User Manual).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
8 participants (estimated)
Patient registry
No

Groups and cohorts

  • Wellness Wearable System & Smartphone
06

What researchers measure

Primary outcomes

  1. detect and predict mood changes in cyclothymic subjects and in rapid cycling subjects

    recording heart rate, respiratory rate and body activity with a wearable device ("Wearable Wellness System" or WWS), and by analysing subject's voice through a voice analysis system embedded in a smartphone.

    Time frame: 14-week study assessment

Secondary outcomes

  1. tolerability and acceptability of the regular use of PSYCHE multiparameter platform (WWS and the smartphone)and the feasibility and the different functionalities of the different components of the PSYCHE system in a field trial

    Evaluation criteria will be : 1. Subjective : the proportions of subjects with tolerance problems and with acceptance of future use, for the different components of the system, as assessed with the end-of-study criteria or as reported at the end of the visits on the basis of an open question ; 2. Objective: the proportion of missing appointments (daily and biweekly recordings) . Evaluation criteria will be : 1) Subjective : the proportions of subjects with tolerance problems and with acceptance of future use, for the different components of the system, as assessed with the end-of-study criteria or as reported at the end of the visits on the basis of an open question ; 2) Objective: the proportion of missing appointments (daily and biweekly recordings) 3) Evaluation criteria will be the estimated frequencies and types of technical and professional user problems during the study (according to a qualitative methodology)

    Time frame: 14-week assessment study

07

Study locations

1 of 1 sites recruiting
  • Service de Psychiatrie II - Hôpitaux Universitaires de Strasbourg
    Strasbourg, Alsace 67 091, France
    Recruiting
08

References and documents

Related links

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01879982
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jun 18, 2013
Start date
May 2013
Primary completion
Dec 2013 (estimated)
Last update
Jun 18, 2013

Study contacts

Bertschy Gilles, MD
principal investigator · Service de Psychiatrie II - Hôpitaux Universitaires de Strasbourg

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion